The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to provide information and records regarding their business practices within 90 days, the agency announced today. FTC said the inquiry will scrutinize the impact of vertically integrated PBMs on the access and affordability of prescription drugs. 

AHA last month urged the FTC to investigate certain practices by health plans and pharmacy benefit manager, commonly referred to as “white bagging,” which disallow health care providers from procuring and managing the drugs they administer to patients.

“As large health plans engage in broad vertical integration efforts, including the acquisition of PBMs and specialty pharmacies, the practice of mandated white bagging has increased dramatically,” forcing hospitals and health systems “to navigate substantial supply chain and logistical challenges in order to continue to provide safe and effective care to the patients they treat,” AHA told the agency. 

Related News Articles

Headline
The House last night voted 220-210 to pass legislation (H.R.382) that would immediately terminate the COVID-19 public health emergency, and 227-203 to pass…
Headline
As the Congressional Telehealth Caucus considers updates to legislation that would permanently remove all geographic restrictions on Medicare telehealth…
Headline
The Centers for Medicare & Medicaid Services Friday released additional guidance on changes to the Medicaid continuous enrollment requirement under…
Headline
AHA today submitted comments in response to a Centers for Medicare & Medicaid Services’ request for information on potential changes to Essential…
Headline
The Centers for Medicare & Medicaid Services yesterday approved the first Medicaid demonstration to provide a limited set of health care services to…
Blog
According to the CDC, 80% of pregnancy-related deaths can be prevented; that’s a 20% increase from previous years. Know why? That’s actually the theme for…